HASBROUCK HEIGHTS, N.J., March 26, 2012 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to report positive new results from the 52-56 month follow-up study of patients who participated in the company’s U.S. Study NX02-0016 of NX-1207 for the treatment of BPH (benign prostatic hyperplasia or enlarged prostate) completed in 2007. The results of the follow-up study provided evidence confirming the durable benefits from NX-1207 treatment for BPH. Two blinded placebo-controlled Phase III studies of NX-1207 2.5 mg for the treatment of BPH as well as a third open label safety study are currently underway in the U.S. and nearing full enrollment. The company and its European partner, Recordati, recently announced the start of a Phase III clinical trial in Europe for NX-1207 for BPH.
